ORFORGLIPRON 6MG/TAB

Oral GLP-1 receptor agonist

Manufacturer: ZPHC
Active Compound: Orforglipron
Strength: 6 mg per tablet
Quantity: 100 tablets
Form: Oral tablets
Verifiable at: https://validation.zphc.com/

Product Overview

Orforglipron is an orally active, non-peptide GLP-1 receptor agonist. Unlike peptide-based GLP-1 medications that are commonly administered by injection (semaglutide, tirzepatide, retatrutide), orforglipron is a small-molecule compound designed for once-daily oral administration.

Orforglipron increases satiety, reduces appetite and food intake, delays gastric emptying, enhances glucose-dependent insulin secretion and reduces glucagon secretion.

Clinical Research & Weight-Loss Results

In the Phase 3 ATTAIN-1 trial, involving 3,127 participants with obesity but without diabetes, evaluated 6 mg, 12 mg and 36 mg once daily for 72 weeks. Under the treatment-regimen analysis, average weight loss was approximately:

6 mg: −7.5%
12 mg: −8.4%
36 mg: −11.2%
Placebo: −2.1%

At 36 mg, 54.6% of participants lost at least 10% of their body weight, 36.0% lost at least 15%, and 18.4% lost at least 20%.

Safety Profile in Clinical Trials

The most frequently reported adverse effects in trials have been gastrointestinal and broadly consistent with the GLP-1 receptor agonist class, including:

• nausea
• diarrhea
• vomiting
• constipation
• dyspepsia

These effects have generally been mild to moderate and have occurred most frequently during dose escalation.

___

Information provided here summarizes published research on the active compound orforglipron and does not establish the clinical efficacy, safety, purity or regulatory status of this specific product.

Clinical-trial doses and outcomes are provided for informational purposes only and are not dosing recommendations. Regulatory status may vary by country. Consult an appropriately qualified healthcare professional before using any product intended to affect body weight, glucose metabolism or other medical conditions.